Palmitoyl Tripeptide-1 is one of the most studied signal peptides in cosmetic science. It appears in the INCI declarations of a wide range of professional anti-aging formulations, often in combination with Palmitoyl Tetrapeptide-7. Understanding its mechanism — not just its marketing claims — is essential for formulators who want to use it effectively.

The Matrikine Hypothesis

The scientific rationale for Palmitoyl Tripeptide-1 begins with matrikines: small peptide fragments released during the degradation of extracellular matrix (ECM) proteins. When collagen is broken down by matrix metalloproteinases (MMPs), the resulting fragments act as biological signals, triggering fibroblasts to synthesise new collagen to repair the matrix.

The tripeptide sequence Glycine-Histidine-Lysine (GHK) is one such matrikine. It is released during collagen Type I degradation and has been shown to stimulate fibroblast proliferation and upregulate the synthesis of collagen, elastin, and glycosaminoglycans.

Palmitoyl Tripeptide-1 is GHK conjugated with palmitic acid at the N-terminus. The palmitoyl chain serves two purposes: it increases the lipophilicity of the peptide, improving penetration through the stratum corneum, and it provides stability against enzymatic degradation in the skin.

Mechanism of Action: The TGF-β Pathway

Palmitoyl Tripeptide-1 activates fibroblasts primarily through the TGF-β (Transforming Growth Factor beta) signalling pathway. TGF-β is a cytokine that plays a central role in wound healing and ECM remodelling. When Palmitoyl Tripeptide-1 binds to fibroblast surface receptors, it triggers downstream signalling that upregulates collagen and elastin synthesis, glycosaminoglycan (GAG) production, and MMP inhibition — collectively supporting dermal matrix renewal.

Evidence

In vitro, 20 ppm (0.002%) increased collagen synthesis by 48.2% and elastin synthesis by 39.1% (supplier data). These figures are from controlled in vitro assays and should be considered as indicative of mechanism; claims for finished products must be substantiated for the specific formulation.

The combination with Palmitoyl Tetrapeptide-7 is well-studied. Palmitoyl Tetrapeptide-7 supports reduction of IL-6, IL-8, and TNF-alpha — pro-inflammatory cytokines that drive chronic low-grade inflammation in aged skin. It also supports laminin, fibronectin, and collagen synthesis. By addressing both the anabolic (collagen synthesis) and catabolic (inflammation-driven degradation) aspects of skin aging, the combination delivers a more comprehensive anti-aging effect than either peptide alone.

UNIPEP MatrixPro 3000 combines Palmitoyl Tripeptide-1 and Palmitoyl Tetrapeptide-7 in a single ingredient, simplifying formulation while delivering the dual-mechanism benefit.

Formulation Guidance

Recommended use level (Palmitoyl Tripeptide-1 / UNIPEP Collagenix-1): 0.01–0.1% as pure powder (as supplied)

Recommended use level (Palmitoyl Tetrapeptide-7): 0.001–0.1% as pure powder (as supplied)

pH: Confirm the stable pH window by stability testing. Optimal activity is generally observed at pH 5.5–6.5, consistent with the skin's natural pH.

Temperature: Add to the water phase at temperatures below 40°C.

Solubility: Palmitoyl Tripeptide-1 is partly soluble in water (below 1000 ppm). In high-oil formulations or at higher concentrations, pre-dissolve in a small amount of propylene glycol or glycerin.

Incompatibilities: Strong acids, strong bases, and strong oxidising agents. Confirm compatibility by stability testing.

Delivery systems: While Palmitoyl Tripeptide-1 may reach deeper skin layers due to its lipophilic palmitoyl chain, encapsulation in liposomes or nanoparticles can further enhance delivery to the target fibroblast layer.

Storage: Store peptide powders at 2–8 °C in tight containers. Shelf life is 24 months under these conditions.

Claim Substantiation

Palmitoyl Tripeptide-1 supports the following claim directions in EU-compliant cosmetic formulations, subject to substantiation for the finished product:

• Stimulates collagen and elastin synthesis
• Improves skin firmness
• Reduces the appearance of fine lines and wrinkles
• Supports skin matrix renewal

Claims must be substantiated for the finished product and must comply with Regulation (EU) No 655/2013 on cosmetic product claims.

UNIPEP Collagenix-1 and Collagenix-5

UNIPEP offers two Palmitoyl Tripeptide-based actives:

UNIPEP Collagenix-1 delivers Palmitoyl Tripeptide-1 as a standalone active, targeting collagen and elastin stimulation via the TGF-β pathway.

UNIPEP Collagenix-5 delivers Palmitoyl Tripeptide-5, which mimics the collagen-stimulating activity of Thrombospondin-1 (TSP-1) and activates TGF-β pathways through a complementary mechanism. It promotes collagen I and elastin synthesis; in vivo, a 100 ppm serum improved skin firmness by 16.2% after 4 weeks (supplier data). Solubility: slightly soluble; glycerol helps with dispersion.

Recommended use level (Palmitoyl Tripeptide-5 / UNIPEP Collagenix-5): 0.001–0.1% as pure powder (as supplied)

Both actives are available with full Technical Data Sheets. Contact the Unikema team to request samples or discuss formulation support.